(12) **Translation of European patent specification**

(11) **NO/EP 3179992 B1**

NORWAY

(19) NO

(51) Int Cl.

A61K 39/395 (2006.01) ***A61K 31/454 (2006.01)***
A61K 31/00 (2006.01) ***A61K 31/519 (2006.01)***
A61K 31/4155 (2006.01) ***A61K 45/06 (2006.01)***
A61K 31/416 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.07.18
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.05.11
(86)	European Application Nr.	15762756.3
(86)	European Filing Date	2015.08.11
(87)	The European Application's Publication Date	2017.06.21
(30)	Priority	2014.08.11, US, 201462035812 P 2014.12.05, US, 201462088357 P 2015.02.12, US, 201562115489 P 2015.06.17, US, 201562181164 P
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
	Designated Extension States:	BA; ME
	Designated Validation States:	MA
(73)	Proprietor	Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss, Nederland
(72)	Inventor	HAMDY, Ahmed, 640 Henry Cowell Drive, Santa Cruz, CA 95060, USA ROTHBAUM, Wayne, 101 Central Park West PHC, New York, NY 10023, USA IZUMI, Raquel, 3437 Brittan Avenue, San Carlos, CA 94070, USA LANNUTTI, Brian, 627 Glencrest Place, Solana Beach, CA 92075, USA COVEY, Todd, 3437 Brittan Avenue, San Carlos, CA 94070, USA ULRICH, Roger, 22525 SE 46th Place, Sammamish, WA 98075, USA JOHNSON, Dave, 694 St. Andrew Circle, Aptos, CA 95033, USA BARF, Tjeerd, St. Luciastraat 7, 5371 AS Ravenstein, Nederland KAPTEIN, Allard, Marten van Rossemsingel 51, 5301 HB Zaltbommel, Nederland
(74)	Agent or Attorney	RWS, Europa House, Chiltern Park, Chiltern Hill, SL99FG CHALFONT ST PETER, Storbritannia

(54) Title **THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR**

(56) References Cited:
WO-A1-2015/061752
WO-A1-2013/010868

BIN CHEN ET AL: "Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells", PLOS ONE, vol. 10, no. 6, 10 June 2015 (2015-06-10), page e0129663, XP055218386, US ISSN: 1932-6203, DOI: 10.1371/journal.pone.0129663
E KLYUCHNIKOV ET AL: "Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?", BONE MARROW TRANSPLANTATION, vol. 49, no. 1, 27 May 2013 (2013-05-27), pages 1-7, XP055217963, GB ISSN: 0268-3369, DOI: 10.1038/bmt.2013.72
D. CHIRON ET AL: "Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma", CANCER DISCOVERY, vol. 4, no. 9, 31 July 2014 (2014-07-31), pages 1022-1035, XP055218352, US ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-14-0098
J. SCHWAMB ET AL: "B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides", BLOOD, vol. 120, no. 19, 8 November 2012 (2012-11-08), pages 3978-3985, XP055218383, US ISSN: 0006-4971, DOI: 10.1182/blood-2012-05-431783
IDIT SAGIV-BARFI ET AL: "Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 112, no. 9, 17 February 2015 (2015-02-17), pages E966-E972, XP055217955, US ISSN: 0027-8424, DOI: 10.1073/pnas.1500712112
G. K. PHILIPS ET AL: "Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies", INTERNATIONAL IMMUNOLOGY., vol. 27, no. 1, 16 October 2014 (2014-10-16), pages 39-46, XP055217958, GB ISSN: 0953-8178, DOI: 10.1093/intimm/dxu095
D'CRUZ OJ ET AL: "Novel Bruton's tyrosine kinase inhibitors currently in development", ONCOTARGETS AND THERAPY, vol. 6, 6 March 2013 (2013-03-06), pages 161-176, XP055217561, GB ISSN: 1178-6930, DOI: 10.2147/OTT.S33732
QINGJIE LIU ET AL: "Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 25, no. 19, 6 August 2015 (2015-08-06), pages 4265-4269, XP055218382, AMSTERDAM, NL ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2015.07.102
HONG D S ET AL: "A multicenter study of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors", JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, USA, vol. 36, no. 15, Supplement 1, 1 May 2018 (2018-05-01), page 2578, XP009511915, ISSN: 1527-7755, DOI: 10.1200/JCO.2018.36.15_SUPPL.2578
HANTSCHEL O: "Targeting BCR-ABL and JAK2 in Ph+ ALL", BLOOD 20150226 AMERICAN SOCIETY OF HEMATOLOGY USA, vol. 125, no. 9, 26 February 2015 (2015-02-26), pages 1362-1363, XP008177695, ISSN: 0006-4971
GIROTTI MARIA ROMINA ET AL: "No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients", MOLECULAR ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 8, no. 6, 15 August 2014 (2014-08-15) , pages 1140-1158, XP029054008, ISSN: 1574-7891, DOI: 10.1016/J.MOLONC.2014.07.027
SONGDEJ NATTHAPOL ET AL: "GIST Treatment Options after Tyrosine Kinase Inhibitors", CURRENT TREATMENT OPTIONS IN ONCOLOGY MAY 2005, SPRINGER US, BOSTON, vol. 15, no. 3, 22 June 2014 (2014-06-22), pages 493-506, XP035381545, ISSN: 1527-2729, DOI: 10.1007/S11864-014-0295-3 [retrieved on 2014-06-22]
GRISAFI DAVIDE ET AL: "Ibrutinib: from bench side to clinical implications", MEDICAL ONCOLOGY, SCIENCE AND TECHNOLOGY LETTERS, NORTHWOOD, GB, vol. 32, no. 9, 30 July 2015 (2015-07-30), pages 1-10, XP035522374, ISSN: 1357-0560, DOI: 10.1007/S12032-015-0669-9 [retrieved on 2015-07-30]
BRIAN J. PARK ET AL: "Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines - Lessons for design of combination targeted therapy", CANCER LETTERS, vol. 320, no. 1, 2 February 2012 (2012-02-02), pages 104-110, XP055217954, US ISSN: 0304-3835, DOI: 10.1016/j.canlet.2012.01.039
VAN DEN AKKER EMILE ET AL: "The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity", BIOLOGICAL CHEMISTRY, vol. 385, no. 5, May 2004 (2004-05), pages 409-413, XP008177694, ISSN: 1431-6730
ZHANG QING ET AL: "[Effect of PI3K[delta] inhibitor CAL-101 on myeloma cell lines and preliminary study of synergistic effects with other new drugs].", ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI OCT 2014, vol. 35, no. 10, October 2014 (2014-10), pages 926-930, XP008177739, ISSN: 0253-2727

JENNIFER L. YORI ET AL: "Abstract LB-221: Inhibition of rapamycin-induced feedback activation of AKT with dasatinib induces complete tumor regression in a preclinical model of breast cancer.", CANCER RESEARCH, vol. 73, no. 8, Suppl. 1, 15 April 2013 (2013-04-15), - 10 April 2013 (2013-04-10), pages LB-221, XP055217951, US ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2013-LB-221

STEPHENS DEBORAH M ET AL: "Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype", BLOOD, vol. 122, no. 21, November 2013 (2013-11), page 2872, XP008177696, & 55TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; NEW ORLEANS, LA, USA; DECEMBER 07 -10, 2013

L. A. MATHEWS GRINER ET AL: "High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 111, no. 6, 27 January 2014 (2014-01-27), pages 2349-2354, XP055218384, US ISSN: 0027-8424, DOI: 10.1073/pnas.1311846111

Patentkrav

1. Farmasøytisk kombinasjon som omfatter (1) en programmert død 1 (PD-1)-hemmer eller en programmert død-ligand 1 (PD-L1)-hemmer og (2) en Brutons tyrosinkinase (BTK)-hemmer eller et farmasøytisk akseptabelt salt av dette til bruk i behandling av kreft hos et menneske, der BTK-hemmeren er valgt fra gruppen som består av:



der PD-1-hememren er pembrolizumab, og PD-L1-hememren er durvalumab.

2. Farmasøytisk kombinasjon til bruk ifølge krav 1, der kombinasjonen omfatter PD-1-hemmeren pembrolizumab.

3. Farmasøytisk kombinasjon til bruk ifølge krav 1, der kombinasjonen omfatter PD-L1-hemmeren durvalumab.

4. Farmasøytisk kombinasjon til bruk ifølge et foregående krav, der kombinasjonen ytterligere omfatter et anti-CD20-antistoff valgt fra gruppen som består av rituksimab, obinutuzumab, ofatumumab, veltuzumab, tositumomab, ^{131}I-tositumomab, ibritumomab, ^{90}Y-ibritumomab, ^{111}In-ibritumomab og ibritumomabtiuksetan.

5. Farmasøytisk kombinasjon til bruk ifølge et foregående krav, der kreften er en hematologisk B-cellemalignitet valgt fra gruppen som består av kronisk lymfocyttleukemi (CLL), småcellet lymfocyttleukemi (SLL), ikke-Hodgkins lymfom (NHL), diffust storcellet B-cellelymfom (DLBCL), follikulært lymfom (FL), mantelcellelymfom (MCL), Hodgkins lymfom, akutt B-cellelymfoblastleukemi (B-ALL), Burkitts lymfom, Waldenströms makroglobulinemi (WM), multippelt myelom (MM), myelodysplastisk syndrom og myelofibrose.

6. Farmasøytisk kombinasjon til bruk ifølge et foregående krav, der kreften er kronisk lymfocyttleukemi (CLL).

7. Farmasøytisk kombinasjon til bruk ifølge et foregående krav, der kreften er diffust storcellet B-cellelymfom (DLBCL).

8. Farmasøytisk kombinasjon til bruk ifølge et foregående krav, der kreften er mantelcellelymfom (MCL).

9. Farmasøytisk kombinasjon til bruk ifølge et av kravene 1 til 8, der bruken omfatter å administrere PD-1- eller PD-L1-hemmeren og BTK-hemmeren samtidig i separate sammensetninger.

10. Farmasøytisk kombinasjon til bruk ifølge et av kravene 1 til 8, der bruken omfatter å administrere PD-1- eller PD-L1-hemmeren og BTK-hemmeren til ulike tider i separate sammensetninger.

11. Farmasøytisk kombinasjon til bruk ifølge et av kravene 1 til 8, der bruken omfatter å administrere PD-1- eller PD-L1-hemmeren og BTK-hemmeren i en sammensetning der to eller flere aktive farmasøytiske ingredienser er til stede.